350 rub
Journal №10 for 2012 г.
Article in number:
Comparative Analysis of Matrix Metalloproteinase-2 in Blood Serum and Tumors 64 of Patients with Malignant, Borderline and Benign Ovarian Neoplasms
Keywords: MMP-2 ovarian tumors blood serum
Authors:
Yu.V. Kryuk, I.V. Tereshkina, G.N. Shvetsova, V.D. Ermilova, A.K. Antonov
Abstract:
The pretreatment data of matrix metalloproteinase-2 in blood serum and tumors 64 of patients with malignant, borderline and benign ovarian neoplasms, with standard immuno-enzymatic reagents of «R&D» company USA, control group were presented 20 people of healthy. No differences were found between MMP-2 levels in the tumors and sera of cancer, benign or borderline tumor patients, and in control group. MMP-2 concentration in the serum of benign ovarian tumor patients was not associated with the main clinico-pathologic features of the disease. Significant increase of MMP-2 levels was revealed in the sera of patients with bilateral ovarian cancer. The highest MMP-2 values were found in blood serum and tumors in serous cancer, moderate and low tumor differentiation grade, stage III-IV disease, and in patients with ascites.
Pages: 36-40
References
  1. Герштейн Е.С., Левкина Н.В., Дигаева М.А., Лактионов К.П., Терешкина И.В., Кушлинский Н.Е. Матриксные металлопротеиназы 2, 7, 9 и тканевой ингибитор матриксных металлопротеиназ 1-го типа в опухолях и сыворотке крови больных новообразованиями яичников // Бюл-летень экспериментальной биологии медицины. 2010.
    Т. 149. № 5. C. 562-565.
  2. Урманчеева А.Ф., Мешкова И.Е. Вопросы эпидемиологии и диагностики рака яичников // В кн. «Практическая онкология: избранные лекции» / под ред. А.Ф. Урманчеевой, С.А. Тюляндина, В.М. Моисеенко.СПб.: Издательство «Центр ТОММ». 2008. C. 320-330.
  3. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression // Nat. Rev. Cancer. 2002. V. 2. № 3. Р. 161-174.
  4. Ellerbroek S.M., Halbleib J.M., Benavidez M., et al. Phospha­tidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association // Cancer Res. 2001. V. 61. № 5. Р. 1855-1861.
  5. Kenny H.E., Lengyel E. MMP-2 functions as an early response protein in ovarian cancer metastasis // Cell Cycle. 2009. V. 8. № 5. P. 683-688.
  6. Lin S.W., Lee M.T., Ke F.C., et al. TGFbeta1 stimulates the secretion of matrix metalloproteinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103 // Clin. Exp. Metastasis. 2000. V. 18. № 6. P. 493-499.
  7. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview // Front. Biosci. 2006. V. 11. P. 1696-1701.
  8. Ramnath N., Creaven P.J. Matrix metalloproteinase inhibitors // Curr. Oncol. Rep. 2004. V. 6. №2. P. 96-102.
  9. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry // Circ. Res. 2003. V. 92. № 8. P. 827-839.
  10. Wang F.Q., Smicun Y., N.Calluzzo N. Fishman Inhibition of matrilysin expression by antisense or RNA interference decreases lysophosphatidic acid-induced epithelial ovarian cancer invasion // Mol. Cancer Res. 2006. V. 4. № 11. P. 831-841.